Waste Management's fourth-quarter revenue fell short of Wall Street forecasts, yet the company demonstrated robust margin expansion through disciplined cost management and strategic integration of acquisitions, setting a firm foundation for its 2026 outlook.
Morgan Stanley and Evercore ISI reaffirm bullish ratings on iRhythm, citing strong Q4 preliminary results and growth potential from its next-gen cardiac monitoring technology.
Guggenheim analyst Subbu Nambi raises her price target on Bruker Corporation (BRKR) from $53 to $58, maintaining a Buy rating and projecting nearly 25% upside, as the life sciences tools sector shows resilience.
Boston Scientific (BSX) is attracting bullish analyst attention after its strategic acquisition of Penumbra, with Truist Securities reiterating a Buy rating and a $120 price target, citing enhanced business durability and growth prospects.
Despite near-term headwinds in its Nutrition segment, Abbott Laboratories (ABT) maintains a bullish long-term outlook with solid organic sales growth projected for 2026, even as major analysts adjust their price targets following Q4 results.
Wall Street analysts are raising price targets on Edwards Lifesciences, citing a renewed growth cycle driven by TAVR expansion and a strong product pipeline, positioning the medical device maker as a favored pick.
A pivotal week for prediction markets saw Coinbase partner with Kalshi to offer event contracts nationwide, while the CFTC moved to establish clearer regulatory standards. Meanwhile, traders sharply increased bets on a potential U.S. government shutdown.
Arabica and robusta coffee futures tumbled sharply on Monday, pressured by forecasts of beneficial rains in Brazil's key growing region and expectations of ample global supplies, with arabica hitting a 5.5-month low.
Weekly unemployment filings in New York state rose last week, contrasting with a slight national decline and highlighting regional economic disparities.
Allegro MicroSystems (ALGM) reported strong fourth-quarter results, with revenue surging 29% year-over-year to $229.2 million, surpassing analyst expectations. The chip designer's growth was fueled by record data center sales and robust demand in automotive, particularly for electric vehicles and ADAS.
OneWater Marine's Q4 results reveal a company successfully steering through a challenging market. While revenue growth was minimal, strategic inventory management and a focus on higher-margin segments led to significant profit improvement, offering a blueprint for resilience in the marine industry.
The global professional services giant reported stronger-than-expected fourth-quarter results, with revenue climbing 8.7% to $6.60 billion. Strategic investments in digital infrastructure and artificial intelligence are credited for driving growth despite headwinds in insurance pricing.
Mastercard's Q4 2025 results surpassed profit expectations, driven by strong demand for its value-added services and key global partnerships, highlighting the payments giant's resilience amid economic uncertainty.
Usama Ghanem, an Egyptian student at King's College London, faces imminent deportation after disciplinary action linked to his pro-Palestinian activism. He claims the university's response mirrors the political persecution he fled in Egypt, raising urgent questions about academic freedom and the treatment of international dissent.
Fueled by surging global demand for its Hoka and Ugg brands, Deckers Outdoor Corp. posted a robust third-quarter performance that surpassed expectations, driving its stock price up sharply and assuaging recent Wall Street concerns over growth sustainability.
Nelnet (NNI) reaffirms its commitment to shareholders with a steady dividend, backed by strong historical revenue growth and share buybacks. Yet, a closer look reveals a complex valuation picture, with contrasting signals from its P/E ratio and discounted cash flow model, leaving analysts divided on the stock's true worth.
Novo Nordisk charts a bold new course, launching a pivotal oral obesity drug while restructuring its workforce and deepening its investment in next-generation cell therapies for metabolic diseases.
Walmart announces CEO Doug McMillon's retirement, appointing tech veterans John Furner and David Guggina to lead its next chapter. The move underscores the retail giant's intensified focus on digital transformation amid strong shareholder returns.
Barclays' upgrade of PTC Therapeutics to Overweight has spotlighted the biotech firm's valuation, with shares showing strong momentum but questions lingering over its path to profitability and reliance on a narrow drug portfolio.
Deere & Company is doubling down on American manufacturing with a new excavator plant and parts center, part of a broader $20 billion commitment. While the move strengthens its long-term industrial narrative, near-term challenges from leadership changes to cyclical market pressures remain in focus.
